Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of British Columbia

$27,000.00

Developing DUSP4/6 small molecule inhibitors for lung adenocarcinoma

FY 2024-25

Summary
Lung cancer (LC) remains the main cause of cancer related deaths worldwide, and will be the cause of around 23% of all cancer deaths in 2024 in Canada. This is largely due to limited treatment options with curative potential. Patients with LC, often harbor mutations in oncogenes: genes that can promote tumor progression. While our understanding of cancer biology and the genetics underlying cancer progression has improved, treatment of LC still poses a clinical challenge as almost all patients develop resistance to current therapeutics. Thus, this highlights the urgent need for new treatment strategies.While most therapeutics aim to inhibit the function of genes, by putting the brakes on the signals that promote tumor growth, it has been shown that cancer cells can also be targeted by increasing certain signals, analogous to pressing on the gas pedal. This project will exploit a vulnerability unique to tumors by targeting cancer cells through upregulated signaling. This can be compared to making the engine of the cancer cells overheat, leading to cell death. An innovative approach like this holds potential for being able to bypass resistance mechanisms that hinder current LC treatments. More specifically, we aim to screen, identify and evaluate the efficacy of small molecule inhibitors that target the dual-specificity phosphatases DUSP6 and DUSP4 for their potential as therapeutics in LC. These enzymes act as regulators by preventing signals from surpassing optimal levels in cancer cells. Thus, these enzymes play a role in the development of cancer and pose potential targets for novel therapies. The results of this work will increase our understanding of LC progression and lay the groundwork for establishing a novel therapy that improves patient outcomes.
Program
Master's Award: Canada Graduate Scholarships
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
530382
Name
Subramaniam Asha
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Developing DUSP4/6 small molecule inhibitors for lung adenocarcinoma
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Genetic Mutation; Lung Adenocarcinoma; Oncogene; Protein Interactions; Signaling Pathways; Structure-Activity Relationship; Thermal Proteome Profiling
Abstract
Lung cancer (LC) remains the main cause of cancer related deaths worldwide, and will be the cause of around 23% of all cancer deaths in 2024 in Canada. This is largely due to limited treatment options with curative potential. Patients with LC, often harbor mutations in oncogenes: genes that can promote tumor progression. While our understanding of cancer biology and the genetics underlying cancer progression has improved, treatment of LC still poses a clinical challenge as almost all patients develop resistance to current therapeutics. Thus, this highlights the urgent need for new treatment strategies.While most therapeutics aim to inhibit the function of genes, by putting the brakes on the signals that promote tumor growth, it has been shown that cancer cells can also be targeted by increasing certain signals, analogous to pressing on the gas pedal. This project will exploit a vulnerability unique to tumors by targeting cancer cells through upregulated signaling. This can be compared to making the engine of the cancer cells overheat, leading to cell death. An innovative approach like this holds potential for being able to bypass resistance mechanisms that hinder current LC treatments. More specifically, we aim to screen, identify and evaluate the efficacy of small molecule inhibitors that target the dual-specificity phosphatases DUSP6 and DUSP4 for their potential as therapeutics in LC. These enzymes act as regulators by preventing signals from surpassing optimal levels in cancer cells. Thus, these enzymes play a role in the development of cancer and pose potential targets for novel therapies. The results of this work will increase our understanding of LC progression and lay the groundwork for establishing a novel therapy that improves patient outcomes.
Competitiondate
202412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Subramaniam, Asha
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~